The Relationship of Carotid Intima-Media Thickness with Cell Adhesion Molecules and Pentraxin-3 in Patients with Psoriatic Arthritis

Abstract Aim Cardiovascular morbidity is increased in patients with psoriatic arthritis (PsA) compared to the general population. Several recent studies have indicated that pentraxin 3 (PTX-3) and cell adhesion molecules (CAMs) might be independent biomarkers of subclinical atherosclerosis. In this study, we aimed to determine the relationship of CAMs and PTX-3 with carotid intima media thickness (CIMT) in patients with PsA and to compare CIMT and serum levels of these biomarkers in patients with healthy controls (HCs). Method PsA patients fulfilling the CASPAR (Classification criteria for Psoriatic Arthritis) criteria without traditional cardiovascular (CV) comorbidity and HCs without autoimmune and/or CV disease were included in this cross-sectional study. Carotid artery Doppler ultrasound examinations were conducted by a single radiologist blinded to the participants’ clinical characteristics. Serum vascular adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), E-selectin, and PTX-3 concentrations were analized. Results 43 PsA patients (27 females, mean age 42.49±11.70 years, and a mean disease duration of 9.37±7.96 years) and 37 HCs (28 females, mean age 42.16±11.38 years) were included. In regression analyses, age and PTX-3 were found to be the best predictors of CIMT in patients with PsA. CIMT was significantly higher in PsA patients compared with HCs (0.63±0.18 vs. 0.49±0.10 mm, p<0.01). In te PsA group, serum levels of PTX-3, ICAM-1, and VCAM-1 were also significantly higher than HCs. CIMT correlated positively with age, disease duration, PTX-3, ICAM-1, and VCAM-1 (p<0.05). Conclusion In our study, age and serum level of PTX-3 were found to be the predictors of CIMT in patients with PsA without CV comorbidity. This outcome highlights the importance of monitoring CIMT and serum level of PTX-3 as CV risk factors in PsA patients.

[1]  W. Schmidt,et al.  Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial , 2021, Trials.

[2]  C. Little,et al.  Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis , 2021, International journal of rheumatic diseases.

[3]  L. Coates,et al.  Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial , 2020, Annals of the Rheumatic Diseases.

[4]  M. Tomšič,et al.  The cut-off values for the intima-media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries. , 2020, Rheumatology.

[5]  Ş. Balta Endothelial dysfunction and inflammatory markers of vascular disease. , 2020, Current vascular pharmacology.

[6]  U. Fearon,et al.  Enhanced angiogenic function in response to fibroblasts from psoriatic arthritis synovium compared to rheumatoid arthritis , 2019, Arthritis Research & Therapy.

[7]  A. Mantovani,et al.  Pentraxin 3 in Cardiovascular Disease , 2019, Front. Immunol..

[8]  M. Hirata,et al.  Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions , 2018, Clinics.

[9]  E. Kerzberg,et al.  Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors , 2018, Front. Immunol..

[10]  M. Chang,et al.  Underestimation of Risk of Carotid Subclinical Atherosclerosis by Cardiovascular Risk Scores in Patients with Psoriatic Arthritis , 2017, The Journal of Rheumatology.

[11]  E. Üstüner,et al.  AB0762 The relationship between serum pentraxin-3 levels, cardiovascular disease risk and disease activity in psoriatic arthritis patients , 2017 .

[12]  P. Krishan,et al.  Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis Using Imaging Technique and Laboratory Markers of Inflammation and Vascular Function , 2016, International Journal of Angiology.

[13]  S. Doǧru-Abbasoǧlu,et al.  Serum Visfatin, Fetuin‐A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity , 2016, Journal of clinical laboratory analysis.

[14]  T. Kawada,et al.  Metabolic syndrome showed significant relationship with carotid atherosclerosis , 2016, Heart and Vessels.

[15]  S. Tas,et al.  Targeting of proangiogenic signalling pathways in chronic inflammation , 2016, Nature Reviews Rheumatology.

[16]  E. Tremoli,et al.  Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies , 2015, Annals of medicine.

[17]  F. Yilmaz,et al.  The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. , 2014, European review for medical and pharmacological sciences.

[18]  M. Schoels Psoriatic arthritis indices. , 2014, Clinical and experimental rheumatology.

[19]  M. González-Gay,et al.  Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[20]  S. Arias-Santiago,et al.  SAT0295 Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls , 2013 .

[21]  M. Turiel,et al.  Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Psoriatic Arthritis , 2011, The Journal of Rheumatology.

[22]  C. Mok,et al.  Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. , 2011, Arthritis and rheumatism.

[23]  L. Coates,et al.  Development of a preliminary composite disease activity index in psoriatic arthritis , 2010, Annals of the rheumatic diseases.

[24]  D. Veale,et al.  Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.

[25]  M. Gobbi,et al.  Regulation of leukocyte recruitment by the long pentraxin PTX3 , 2010, Nature Immunology.

[26]  C. Garlanda,et al.  Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis , 2009, Circulation.

[27]  L. Kuller,et al.  Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death: The Cardiovascular Health Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Cheuk-Man Yu,et al.  Subclinical carotid atherosclerosis in patients with psoriatic arthritis. , 2008, Arthritis and rheumatism.

[29]  M. Dougados,et al.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.

[30]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[31]  B. Joffe,et al.  Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis , 2004, Arthritis research & therapy.

[32]  S P McKenna,et al.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[33]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[34]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[35]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[36]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[37]  Özge Darka Hücre Adezyon Molekülleri veEnflamasyondaki Rolleri , 2003 .

[38]  P. Ridker Novel risk factors and markers for coronary disease. , 2000, Advances in internal medicine.

[39]  Ö. Saygili,et al.  Hücre Adezyon Molekülleri , 1999 .

[40]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[41]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[42]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.